Sugi Predict

Sugi Predict / Compounds / SCHEMBL24364822

SCHEMBL24364822

SCHEMBL24364822

CN1CCC(c2nc3cc(B4OC(C)(C)C(C)(C)O4)ccc3s2)C1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SNCA P37840 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ UBE2M P61081 5/20 0.34
▸ DCUN1D1 Q96GG9 5/20 0.34
▸ ALDH1A1 P00352 4/20 0.34
▸ TP53 P04637 2/20 0.34
▸ DRD2 P14416 1/20 0.34
▸ DRD4 P21917 1/20 0.34
▸ GRM2 Q14416 1/20 0.34
▸ LMNA P02545 2/20 0.33
▸ ALOX12 P18054 1/20 0.33
▸ TSHR P16473 2/20 0.33
▸ NPSR1 Q6W5P4 2/20 0.33
▸ GAA P10253 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ STAT3 P40763 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25923038 0.94 KCNH2 (0.35) SNCANPC1RAB9AUBE2MDCUN1D1
SCHEMBL24363858 0.93 NPC1 (0.39) SNCANPC1RAB9AUBE2MDCUN1D1
SCHEMBL24365160 0.91 SNCA (0.38) SNCANPC1RAB9AUBE2MDCUN1D1
SCHEMBL25322155 0.86 SNCA (0.34) SNCA
SCHEMBL30551626 0.86 SNCA (0.34) SNCA
SCHEMBL25336674 0.85 SNCA (0.34) SNCANPC1RAB9A
SCHEMBL25323670 0.85 SNCA (0.34) SNCAALDH1A1GAA
SCHEMBL24366898 0.85 UBE2M (0.35) SNCANPC1RAB9AUBE2MDCUN1D1
SCHEMBL25322458 0.85 NPC1 (0.46) SNCANPC1RAB9ATP53DRD2
SCHEMBL25337326 0.85 SNCA (0.34) SNCANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078117-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS INC (US) 2026-03-19 — — US disclosed
US-20250163048-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-22 — — US disclosed
US-12304907-B2 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2025-05-20 — — US disclosed
US-12264154-B2 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2025-04-01 — — US disclosed
EP-4469455-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 — — EP disclosed
US-20240279219-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-08-22 — — US disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 — — US disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 — — US disclosed
US-11999727-B2 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2024-06-04 — — US disclosed
CN-116568677-A piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers 探戈医药股份有限公司 2023-08-08 — — CN disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed
EP-4188920-A1 PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS Tango Therapeutics, Inc. (US) 2023-06-07 — — EP disclosed
US-20230113778-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2023-04-13 — — US disclosed
US-11492350-B2 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2022-11-08 — — US disclosed
US-20220127256-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2022-04-28 — — US disclosed
US-20220127256-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2022-04-28 — — US disclosed
WO-2022026892-A1 PIPERIDIN-1- YL-N-PYRYDI NE-3-YL-2-OXOACET AM IDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MT A-ACCUMULATING CANCERS TANGO THERAPEUTICS, INC. (US) 2022-02-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11999727-B2 Compounds and methods of use F12, C1R, ABCG2 SNCA 1297/4885NPC1 39/4885RAB9A 320/4885
US-20240279219-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 SNCA 1297/4885NPC1 39/4885RAB9A 320/4885
US-11492350-B2 Compounds and methods of use F12, C1R, ABCG2 SNCA 1297/4885NPC1 39/4885RAB9A 320/4885
US-20230113778-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 SNCA 1297/4885NPC1 39/4885RAB9A 320/4885
US-20250163048-A1 COMPOUNDS AND METHODS OF USE RB1, CYP1B1, REN SNCA 1168/4885NPC1 383/4885RAB9A 324/4885
US-12264154-B2 Compounds and methods of use F12, C1R, ABCG2 SNCA 1297/4885NPC1 39/4885RAB9A 320/4885
US-12304907-B2 Compounds and methods of use F12, C1R, ABCG2 SNCA 1297/4885NPC1 39/4885RAB9A 320/4885
US-20220127256-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 SNCA 1297/4885NPC1 39/4885RAB9A 320/4885
US-20240228478-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 SNCA 1297/4885NPC1 39/4885RAB9A 320/4885
US-20260078117-A1 COMPOUNDS AND METHODS OF USE NR3C2, ADRA1A, CNR1 SNCA 689/4885NPC1 24/4885RAB9A 420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.